Top 20 Cancer Therapy Brands in Australia Forecast

Wednesday, April 28, 2010 Research News J E 4
Top 20 Cancer Therapy Brands in Australia Forecast The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008 growing at a CAGR of 30% since 2005. Datamonitor forecasts this growth to slow down considerably to a CAGR of 5.6% between 2008 and 2018 mainly due to maturing markets and the entry of generics for several key products. Sales of the Top 20 brands are expected to reach a total of $940m in 2018. ( ) Reasons to Purchase Identify key opportunities and threats that will impact the Australian oncology market as a whole and the Top 20 in particular Quantify the future size and scope of the Top 20 Australian cancer therapies market and predict the performance of its key compounds Understand critical success factors in growing and defending cancer brand franchises from new entrants and generics Key chapters of the report : OVERVIEW Introduction Scope of this research Research and analysis highlights Forecasts that the molecular targeted therapies will continue to drive growth in the Australian Top 20 cancer therapies market over the forecast period 2008–2018 with sales increasing from $320m in 2008 to $750m 2018. Key reasons to read this report Forecasting Methodology The forecasting model: General event information: Event selection and quantification: Event parameters: To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Follow us on twitter:


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
WellPoint Reports First Quarter 2010 Results
Effective Market Research Critical to Success in M...